Introduction of AI/ML in Cell and Gene Therapy: Definitions and Data Standardization

ABOUT THE WEBINAR

Join us for the introductory session of a five-part webinar series designed to demystify artificial intelligence (AI), machine learning (ML) and predictive analytics in the cell and gene therapy field. In this first webinar, we’ll break down key AI/ML definitions and discuss why data standardization, including preferred formats, like JSON over PDFs, is crucial for successful digital transformation. We’ll showcase initiatives from NIMBL and NIST designed to enhance information exchange and usability across computer systems and software.

Subsequent webinars will delve into real world examples, showing how ML can accelerate breakthroughs in CGT through predictive analytics, modeling tools, and insightful case studies, such as donor characterisation and T-cell activation tracking.

The series will conclude by looking ahead to regulatory and ethical challenges, practical lifecycle applications of AI across CGT workflows, and considerations for effective tool selection. Whether you’re a biologist, data scientist, or industry leader, this series promises actionable insights and frameworks to bridge disciplines and advance innovation in cell and gene therapy. 

Access the webinar

KEY LEARNING OBJECTIVES

  • Summarize key definition and descriptions of terms relevant to artificial intelligence and machine learning models in context of cell & gene therapy development.
  • Identify examples of data standardization formats and best practices.
 SPEAKERS

Dalip Sethi, PhD, MBA, MS
ISCT PAAD Working Group Co-Chair
Commercial Leader, Cell Therapy Technologies (North America)
Terumo Blood and Cell Technologies
Unites States

Dalip Sethi is a seasoned biotechnology executive with over 15 years of experience, including more than a decade in cell and gene therapy. As Commercial Leader for Cell Therapy Technologies at Terumo Blood and Cell Technologies, Dalip leads strategic initiatives across North America, driving innovation in product development, commercialization, and customer engagement. He currently serves as co-chair of the ISCT PAAD Working Group, where he helps shape industry standards around Process Analytical Technology (PAT) and digital transformation. Dalip recently co-authored a publication focused on the application of artificial intelligence (AI) and machine learning (ML) in cell therapy manufacturing, exploring how these technologies can reduce variability, improve process control, and accelerate development timelines. Dalip’s career spans leadership roles in R&D, including the development of cell isolation technologies and CAR-T manufacturing platforms, as well as commercial strategy and market development. He is passionate about advancing the cell therapy industry through innovation, collaboration, and data-driven decision-making.

Geoffrey Stephens, PhD, MBA
ISCT PAAD Working Group Member 
Founder and CEO
AiCella Inc.
United States

Geoffrey Stephens, PhD, the Founder and CEO of AiCella, Inc., is an experienced scientific executive with more than 20 years of experience working in all aspects of the biotech industry. After graduating with a PhD in Molecular Medicine from the Medical College of Georgia, Dr. Stephens spent four years as a postdoctoral fellow at the National Institute for Allergy and Infectious Diseases (NIAID) at the NIH in Bethesda, MD working under the direction of Ethan Shevach, MD. Following the NIAID, Dr. Stephens spent nine years leading teams in drug discovery and development. His experience spans regulatory T cells, CAR-T, TCR-T, iPSCs, large and small molecule therapeutics for cancer, autoimmunity, and inflammatory diseases. As head of Process Development at Tessa Therapeutics he played an integral role developing CD30-CAR-T cell therapies for the treatment of Hodgkin and non-Hodgkin lymphoma. Dr. Stephens was also the Director of Product Science at Immatics, LLC, where he led the development of TCR-T cell-based therapies for the treatment of a variety of cancers.